GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neon Therapeutics Inc (NAS:NTGN) » Definitions » Current Ratio

Neon Therapeutics (Neon Therapeutics) Current Ratio : 1.58 (As of Mar. 2020)


View and export this data going back to 2018. Start your Free Trial

What is Neon Therapeutics Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Neon Therapeutics's current ratio for the quarter that ended in Mar. 2020 was 1.58.

Neon Therapeutics has a current ratio of 1.58. It generally indicates good short-term financial strength.

The historical rank and industry rank for Neon Therapeutics's Current Ratio or its related term are showing as below:

NTGN's Current Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.79
* Ranked among companies with meaningful Current Ratio only.

Neon Therapeutics Current Ratio Historical Data

The historical data trend for Neon Therapeutics's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neon Therapeutics Current Ratio Chart

Neon Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19
Current Ratio
19.01 9.27 8.31 3.00

Neon Therapeutics Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.30 6.13 4.59 3.00 1.58

Competitive Comparison of Neon Therapeutics's Current Ratio

For the Biotechnology subindustry, Neon Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neon Therapeutics's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neon Therapeutics's Current Ratio distribution charts can be found below:

* The bar in red indicates where Neon Therapeutics's Current Ratio falls into.



Neon Therapeutics Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Neon Therapeutics's Current Ratio for the fiscal year that ended in Dec. 2019 is calculated as

Current Ratio (A: Dec. 2019 )=Total Current Assets (A: Dec. 2019 )/Total Current Liabilities (A: Dec. 2019 )
=31.243/10.407
=3.00

Neon Therapeutics's Current Ratio for the quarter that ended in Mar. 2020 is calculated as

Current Ratio (Q: Mar. 2020 )=Total Current Assets (Q: Mar. 2020 )/Total Current Liabilities (Q: Mar. 2020 )
=17.009/10.767
=1.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neon Therapeutics  (NAS:NTGN) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Neon Therapeutics Current Ratio Related Terms

Thank you for viewing the detailed overview of Neon Therapeutics's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Neon Therapeutics (Neon Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
40 Erie Street, Suite 110, Cambridge, MA, USA, 02139
Neon Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. The company's pipeline products are NEO-PV-01, NEO-PTC-01, and NEO-SV-01.
Executives
Cary Pfeffer director C/O ELEVEN BIOTHERAPEUTICS, 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142
Jolie Siegel officer: VP, General Counsel C/O NEON THERAPEUTICS, INC., 40 ERIE ST., SUITE 110, CAMBRIDGE MA 02139
Robert Kamen director C/O JOUNCE THERAPEUTICS, INC., 1030 MASSACHUSETTS AVENUE, BOSTON MA 02210
Meryl Zausner director C/O NEON THERAPEUTICS, INC., 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
Yasir B. Al-wakeel officer: Chief Financial Officer MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Eric S Lander director 415 MAIN STREET, CAMBRIDGE MA 02142
Stephen A Sherwin director C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080
Robert I Tepper director, 10 percent owner 201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215
Robert B Bazemore director 33 HAYDEN AVE, LEXINGTON MA 02421
Richard Gaynor officer: President of R&D C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
Access Industries, Llc other: Affiliate of 10% Owner 730 FIFTH AVENUE, NEW YORK NY 10019
Access Industries Management, Llc other: Affiliate of 10% Owner 730 FIFTH AVENUE, NEW YORK NY 10019
Access Industries Holdings Llc 10 percent owner C/O ACCESS INDUSTRIES MANAGEMENT, LLC., 730 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10019
Clal Biotechnology Industries Ltd. other: See Remarks 3AZRIELI CENTER TRIANGLE TOWER 45 FLOOR, TEL AVIV L3 67023
Len Blavatnik other: Affiliate of 10% Owner C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019

Neon Therapeutics (Neon Therapeutics) Headlines

From GuruFocus